Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: A population-based case-control study in Shanghai, China

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 3, 2008, Pages 525-534

  Andreotti, Gabriella ^a,i   Chen, Jinbo ^b   Gao, Yu Tang ^c   Rashid, Asif ^d   Chen, Bingshu E ^a   Rosenberg, Philip ^a   Sakoda, Lori C ^e   Deng, Jie ^c   Shen, Ming Chang ^f   Wang, Bing Sheng ^f   Han, Tian Quan ^g   Zhang, Bai He ^h   Yeager, Meredith ⁱ   Welch, Robert ⁱ   Chanock, Stephen ^a,i   Fraumeni Jr , Joseph F ^a   Hsing, Ann W ^a  

^a NIH

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c SHANGHAI CANCER INSTITUTE   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f FUDAN UNIVERSITY   (China)

^g SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^h SECOND MILITARY MEDICAL UNIVERSITY   (China)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; ARACHIDONATE 5 LIPOXYGENASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; AGED; ARTICLE; BILIARY TRACT CANCER; CANCER RISK; CHINA; CONTROLLED STUDY; FEMALE; GALLBLADDER CANCER; GALLSTONE; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ALLELES; BILIARY TRACT NEOPLASMS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHINA; FEMALE; GALLSTONES; GENOTYPE; HAPLOTYPES; HUMANS; INTERVIEWS AS TOPIC; LIPID METABOLISM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; RISK FACTORS; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL; VARIATION (GENETICS);

EID: 41549140713     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2704     Document Type: Article

References (52)

1. Hsing AW, Gao YT, Devesa SS, Jin F, Fraumeni JF Jr. Rising incidence of biliary tract cancers in Shanghai, China. Int J Cancer 1998;75:368-70.
2. Hsing AW, Rashid A, Devesa SS, Fraumeni JF Jr. Biliary tract cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention (edition III). Oxford University Press; 2006. p. 787-800.
3. Lowenfels AB, Walker AM, Althaus DP, Townsend G, Domellof L. Gallstone growth, size, and risk of gallbladder cancer: an interracial study. Int J Epidemiol 1989;18:50-4.
4. Hsing AW, Rashid A, Sakoda L, et al. Gallstone and the risk of biliary tract cancer: a population-based study. Br J Cancer 2007;97:1577-82.
5. Attili AF, Capocaccia R, Carulli N, et al. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis. Hepatology 1997;26:809-18.
6. Singh V, Zaidi SA, Singh VS. Lipids in biliary lithogenesis. J Pak Med Assoc 1997;47:253-5.
7. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999;341:1368-78.
8. Humphries SE, Kessling AM, Horsthemke B, et al. A common DNA polymorphism of the low-density lipoprotein (LDL) receptor gene and its use in diagnosis. Lancet 1985;1:1003-5.
9. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
10. Lopez-Miranda J, Ordovas JM, Ostos MA, et al. Dietary fat clearance in normal subjects is modulated by genetic variation at the apolipoprotein B gene locus. Arterioscler Thromb Vasc Biol 1997;17:1765-73.
11. Aalto-Setala K, Palomaki H, Miettinen H, et al. Genetic risk factors and ischaemic cerebrovascular disease: role of common variation of the genes encoding apolipoproteins and angiotensin-converting enzyme. Ann Med 1998;30:224-33.
12. Skoglund-Andersson C, Ehrenborg E, Fisher RM, Olivecrona G, Hamsten A, Karpe F. Influence of common variants in the CETP, LPL, HL and APO E genes on LDL heterogeneity in healthy, middle-aged men. Atherosclerosis 2003;167:311-7.
13. Poole EM, Bigler J, Whitton J, Sibert JG, Potter JD, Ulrich CM. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2006;15:502-8.
14. Carlson CS, Heagerty PJ, Nord AS, et al. TagSNP evaluation for the association of 42 inflammation loci and vascular disease: evidence of IL6, FGB, ALOX5, NFKBIA, and IL4R loci effects. Hum Genet 2007;121:65-75.
15. Hsing AW, Bai Y, Andreotti G, et al. Family history of gallstones and the risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Int J Cancer 2007;121:832-8.
16. Lusis AJ. Genetic factors affecting blood lipoproteins: the candidate gene approach. J Lipid Res 1988;29:397-429.
17. Juvonen T, Savolainen MJ, Kairaluoma MI, Lajunen LH, Humphries SE, Kesaniemi YA. Polymorphisms at the apoB, apoA-I, and cholesteryl ester transfer protein gene loci in patients with gallbladder disease. J Lipid Res 1995;36:804-12.
18. Hsing AW, Gao YT, McGlynn KA, et al. Biliary tract cancer and stones in relation to chronic liver conditions: a population-based study in Shanghai, China. Int J Cancer 2007;120:1981-5.
19. Packer BR, Yeager M, Burdett L, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006;34:D617-21.
20. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika 1986;73:751-4.
21. Rosenberg PS, Che A, Chen BE. Multiple hypothesis testing strategies for genetic case-control association studies. Stat Med 2006;25:3134-49.
22. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
23. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
24. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-7.
25. Bertomeu A, Ros E, Zambon D, et al. Apolipoprotein E polymorphism and gallstones. Gastroenterology 1996;111:1603-10.
26. Portincasa P, van Erpecum KJ, van De Meeberg PC, Dallinga-Thie GM, de Bruin TW, van Berge-Henegouwen GP. Apolipoprotein E4 genotype and gallbladder motility influence speed of gallstone clearance and risk of recurrence after extracorporeal shock-wave lithotripsy. Hepatology 1996;24:580-7.
27. Boland LL, Folsom AR, Boerwinkle E. Apolipoprotein E genotype and gallbladder disease risk in a large population-based cohort. Ann Epidemiol 2006;16:763-9.
28. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-37.
29. Laskowitz DT, Goel S, Bennett ER, Matthew WD. Apolipoprotein E suppresses glial cell secretion of TNF α. J Neuroimmunol 1997;76:70-4.
30. Lynch JR, Morgan D, Mance J, Matthew WD, Laskowitz DT. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol 2001;114:107-13.
31. Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999;30:1128-33.
32. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000;60:184-90.
33. Hayek T, Oiknine J, Brook JG, Aviram M. Increased plasma and lipoprotein lipid peroxidation in apo E-deficient mice. Biochem Biophys Res Commun 1994;201:1567-74.
34. Vogel T, Guo NH, Guy R, et al. Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem 1994;54:299-308.
35. Lehrer S. Possible relationship of the apolipoprotein E (ApoE) epsilon4 allele to prostate cancer. Br J Cancer 1998;78:1398.
36. Watson MA, Gay L, Stebbings WS, Speakman CT, Bingham SA, Loktionov A. Apolipoprotein E gene polymorphism and colorectal cancer: gender-specific modulation of risk and prognosis. Clin Sci 2003;104:537-45.
37. Chang NW, Chen DR, Wu CT, et al. Influences of apolipoprotein E polymorphism on the risk for breast cancer and HER2/neu status in Taiwan. Breast Cancer Res Treat 2005;90:257-61.
38. Reilly SL, Ferrell RE, Kottke BA, Kamboh MI, Sing CF. The gender-specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. I. Pleiotropic effects on means and variances. Am J Hum Genet 1991;49:1155-66.
39. Gomez-Coronado D, Alvarez JJ, Entrala A, Olmos JM, Herrera E, Lasuncion MA. Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins. Atherosclerosis 1999;147:167-76.
40. Kane JP. Apolipoprotein B: structural and metabolic heterogeneity. Annu Rev Physiol 1983;45:637-50.
41. Law SW, Lackner KJ, Fojo SS, Hospattankar A, Monge JC, Brewer HB Jr. The molecular biology of human apoA-I, apoA-II, apoC-II and apoB. Adv Exp Med Biol 1986;201:151-62.
42. Pallaud C, Gueguen R, Sass C, et al. Genetic influences on lipid metabolism trait variability within the Stanislas Cohort. J Lipid Res 2001;42:1879-90.
43. Wells BJ, Mainous AG III, Everett CJ, Gill JM. Iron, cholesterol, and the risk of cancer in an 18 year cohort. Asian Pac J Cancer Prev 2005;6:505-9.
44. Benitez S, Camacho M, Bancells C, Vila L, Sanchez-Quesada JL, Ordonez-Llanos J. Wide proinflammatory effect of electronegative low-density lipoprotein on human endothelial cells assayed by a protein array. Biochim Biophys Acta 2006;1761:1014-21.
45. Feig DI, Sowers LC, Loeb LA. Reverse chemical mutagenesis: identification of the mutagenic lesions resulting from reactive oxygen species-mediated damage to DNA. Proc Natl Acad Sci U S A 1994;91:6609-13.
46. Rashid A, Ueki T, Gao YT, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res 2002;8:3156-63.
47. Brown MS, Goldstein JL. How LDL receptors influence cholesterol and atherosclerosis. Sci Am 1984;251:58-66.
48. Devesa SS, Silverman DT, Young JL Jr, et al. Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst 1987;79:701-70.
49. Wistuba II, Miquel JF, Gazdar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999;30:21-5.
50. Rashid A, Gao YT, Bhakta S, et al. β-catenin mutations in biliary tract cancers: a population-based study in China. Cancer Res 2001;61:3406-9.
51. Woo D, Kaushal R, Chakraborty R, et al. Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage. Stroke 2005;36:1874-9.
52. Long JR, Liu PY, Liu YJ, et al. APOE haplotypes influence bone mineral density in Caucasian males but not females. Calcif Tissue Int 2004;75:299-304.